Skip to main content
SpringerLink
Log in

Integrated Approach to Coronary Artery Disease

  • Chapter
  • First Online:
Integrative Cardiology

Abstract

About 20 million persons in the United States have coronary heart disease (CHD):10.2 million with angina pectoris and 8.5 million with myocardial infarction [1]. The lifetime risk of developing coronary artery disease for people in middle age is 50 % for men and 30 % for women [2]. According to a 2013–2014 World Health Organization study, over 4 million annual deaths are due to cardiovascular disease, of which ischemic heart disease is the main factor [3]. Mortality from CHD is expected to increase in developing countries from an estimated 9 million in 1990 to a projected 19 million by 2020 [4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lloyd-Jones D et al (2010) Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121:948–954

    Article  PubMed  Google Scholar 

  2. Lerner DJ, Kannel WB (1986) Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 111:383–390

    Article  CAS  PubMed  Google Scholar 

  3. Nichols M, Townsend N, Scarborough P, Rayner M (2013) Cardiovascular disease in Europe: epidemiological update. Eur Heart J 34:3028–3034

    Article  PubMed  Google Scholar 

  4. Okrainec K, Banerjee DK, Eisenberg MJ (2004) Coronary artery disease in the developing world. Am Heart J 148:7–15

    Article  PubMed  Google Scholar 

  5. John Camm A, Luscher TF, Serruys PW (2009) ESC textbook of cardiovascular medicine, 2nd edn. Oxford University Press, Oxford

    Google Scholar 

  6. Go AS et al (2013) Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation 127:e6–e245

    Article  PubMed  Google Scholar 

  7. Ogden CL et al (2006) Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 295:1549–1555

    Article  CAS  PubMed  Google Scholar 

  8. Devries S, Dalen J (2011) Integrative cardiology. Oxford University Press, Oxford, pp 1–324

    Google Scholar 

  9. Dal Lin C et al (2015) Coronary microvascular and endothelial function regulation: crossroads of psychoneuroendocrine immunitary signals and quantum physics [Part A]. J Integr Cardiol 1:132–163

    Google Scholar 

  10. Goldstein BI et al (2015) Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease. Circulation 132:965–986

    Article  PubMed  Google Scholar 

  11. Dal Lin C et al (2015) Coronary microvascular and endothelial function regulation: crossroads of psychoneuroendocrine immunitary signals and quantum physics [Part B]. J Integr Cardiol 1:164–188

    Google Scholar 

  12. Dal Lin C et al (2015) Coronary microvascular and endothelial function regulation: crossroads of psychoneuroendocrine immunitary signals and quantum physics [Part C]. J Integr Cardiol 1:189–209

    Google Scholar 

  13. Dal Lin C, Tona F, Osto E (2015) Coronary microvascular function and beyond: the crosstalk between hormones, cytokines, and neurotransmitters. Int J Endocrinol 2015:1–17

    Article  CAS  Google Scholar 

  14. Narayan KMV, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF (2003) Lifetime risk for diabetes mellitus in the United States. JAMA 290:1884–1890

    Article  CAS  PubMed  Google Scholar 

  15. Olshansky SJ et al (2005) A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 352:1138–1145

    Article  CAS  PubMed  Google Scholar 

  16. Rakel D (2012) Integrative medicine, 3rd edn. Elsevier, Amsterdam

    Google Scholar 

  17. Fani Marvasti F, Stafford RS (2012) From sick care to health care – reengineering prevention into the US System. N Engl J Med 367:889–891

    Article  PubMed  CAS  Google Scholar 

  18. Pizzorno JE, Murray MT, Herb JB (2008) The clinician’s handbook of natural medicine, 2nd edn. Churchill Livingstone, Edinburgh

    Google Scholar 

  19. Riaz IB et al (2014) Meta-analysis of revascularization versus medical therapy for atherosclerotic renal artery stenosis. Am J Cardiol 114:1116–1123

    Article  PubMed  Google Scholar 

  20. Bangalore S, Pursnani S, Kumar S, Bagos PG (2013) Percutaneous coronary intervention versus optimal medical therapy for prevention of spontaneous myocardial infarction in subjects with stable ischemic heart disease. Circulation 127:769–781

    Article  PubMed  Google Scholar 

  21. Thomas S, Gokhale R, Boden WE, Devereaux PJ (2013) A meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with medical therapy in stable angina pectoris. Can J Cardiol 29:472–482

    Article  PubMed  Google Scholar 

  22. Boden WE et al (2009) Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial). Am J Cardiol 104:1–4

    Article  PubMed  Google Scholar 

  23. El-Hayek G et al (2014) Meta-analysis of randomized clinical trials comparing short-term versus long-term dual antiplatelet therapy following drug-eluting stents. Am J Cardiol 114:236–242

    Article  CAS  PubMed  Google Scholar 

  24. Brieger DB, Redfern J (2013) Contemporary themes in acute coronary syndrome management: from acute illness to secondary prevention. Med J Aust 199:174–178

    Article  PubMed  Google Scholar 

  25. Mann JM, Davies MJ (1996) Vulnerable plaque. Relation of characteristics to degree of stenosis in human coronary arteries. Circulation 94:928–931

    Article  CAS  PubMed  Google Scholar 

  26. Falk E, Shah PK, Fuster V (1995) Coronary plaque disruption. Circulation 92:657–671

    Article  CAS  PubMed  Google Scholar 

  27. De Lorgeril M et al (1994) Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 343:1454–1459

    Article  PubMed  Google Scholar 

  28. De Lorgeril M et al (1999) Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 99:779–7785

    Article  PubMed  Google Scholar 

  29. Joshipura KJ et al (2001) The effect of fruit and vegetable intake on risk for coronary heart disease. Ann Intern Med 134:1106–1114

    Article  CAS  PubMed  Google Scholar 

  30. Vogel RA, Corretti MC, Plotnick GD (1997) Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol 79:350–354

    Article  CAS  PubMed  Google Scholar 

  31. Hu FB et al (1999) Dietary saturated fats and their food sources in relation to the risk of coronary heart disease in women. Am J Clin Nutr 70:1001–1008

    CAS  PubMed  Google Scholar 

  32. Daviglus ML et al (1997) Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med 336:1046–1053

    Article  CAS  PubMed  Google Scholar 

  33. Burr ML, et al (1989) Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet (London, England) 2:757–761

    Google Scholar 

  34. Mellen PB, Walsh TF, Herrington DM (2008) Whole grain intake and cardiovascular disease: a meta-analysis. Nutr Metab Cardiovasc Dis 18:283–290

    Article  PubMed  Google Scholar 

  35. Welsh JA et al (2010) Caloric sweetener consumption and dyslipidemia among US adults. JAMA 303:1490–1497

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Hallfrisch J, Behall KM (2000) Mechanisms of the effects of grains on insulin and glucose responses. J Am Coll Nutr 19:320S–325S

    Article  CAS  PubMed  Google Scholar 

  37. Sabaté J, Ang Y (2009) Nuts and health outcomes: new epidemiologic evidence. Am J Clin Nutr 89:1643S–1648S

    Article  PubMed  CAS  Google Scholar 

  38. Ros E, Tapsell LC, Sabaté J (2010) Nuts and berries for heart health. Curr Atheroscler Rep 12:397–406

    Article  CAS  PubMed  Google Scholar 

  39. Janssens J et al (1990) Nutmeg oil: identification and quantitation of its most active constituents as inhibitors of platelet aggregation. J Ethnopharmacol 29:179–188

    Article  CAS  PubMed  Google Scholar 

  40. Su L et al (2007) Total phenolic contents, chelating capacities, and radical-scavenging properties of black peppercorn, nutmeg, rosehip, cinnamon and oregano leaf. Food Chem 100:990–997

    Article  CAS  Google Scholar 

  41. Calliste CA et al (2010) A new antioxidant from wild nutmeg. Food Chem 118:489–496

    Article  CAS  Google Scholar 

  42. Duan W et al (2012) The effects of curcumin post-treatment against myocardial ischemia and reperfusion by activation of the JAK2/STAT3 signaling pathway. Basic Res Cardiol 107:263

    Article  PubMed  CAS  Google Scholar 

  43. Zhang M, Cai S, Ma J (2015) Evaluation of cardio-protective effect of soybean oligosaccharides. Gene 555:329–334

    Article  CAS  PubMed  Google Scholar 

  44. Ge G et al (2014) Protective effect of Salvia miltiorrhiza aqueous extract on myocardium oxidative injury in ischemic-reperfusion rats. Gene 546:97–103

    Article  CAS  PubMed  Google Scholar 

  45. Tanasescu M et al (2002) Exercise type and intensity in relation to coronary heart disease in men. JAMA 288:1994–2000

    Article  PubMed  Google Scholar 

  46. Madanmohan UK, Bhavanani AB, Shatapathy CC, Sahai A (2004) Modulation of cardiovascular response to exercise by yoga training. Indian J Physiol Pharmacol 48:461–465

    CAS  PubMed  Google Scholar 

  47. Yeung A et al (2014) Randomised controlled trial of a 12 week yoga intervention on negative affective states, cardiovascular and cognitive function in post-cardiac rehabilitation patients. BMC Complement Altern Med 14:411

    Article  PubMed  PubMed Central  Google Scholar 

  48. Bergh C, Udumyan R, Fall K, Almroth H, Montgomery S (2015) Stress resilience and physical fitness in adolescence and risk of coronary heart disease in middle age. Heart 101:623–629

    Article  PubMed  PubMed Central  Google Scholar 

  49. Castelli WP (1996) Lipids, risk factors and ischaemic heart disease. Atherosclerosis 124(Suppl):S1–9

    Article  CAS  PubMed  Google Scholar 

  50. Brown L, Rosner B, Willett WW, Sacks FM (1999) Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 69:30–42

    CAS  PubMed  Google Scholar 

  51. Anderson JW et al (2000) Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia. Am J Clin Nutr 71:1433–1438

    CAS  PubMed  Google Scholar 

  52. Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E (1995) Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 333:1308–1312

    Article  CAS  PubMed  Google Scholar 

  53. Norris RB (2006) Flush-free niacin’: dietary supplement may be ‘benefit-free’. Prev Cardiol 9:64–65

    Article  PubMed  Google Scholar 

  54. Papaliodis D, Boucher W, Kempuraj D, Theoharides TC (2008) The flavonoid luteolin inhibits niacin-induced flush. Br J Pharmacol 153:1382–1387

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Heber D et al (1999) Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 69:231–236

    CAS  PubMed  Google Scholar 

  56. Becker DJ et al (2008) Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clin Proc 83:758–764

    Article  CAS  PubMed  Google Scholar 

  57. Gordon RY, Cooperman T, Obermeyer W, Becker DJ (2010) Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med 170:1722–1727

    CAS  PubMed  Google Scholar 

  58. Becker DJ et al (2009) Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 150(830–839):W147–149

    Google Scholar 

  59. Lu Z et al (2008) Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 101:1689–1693

    Article  PubMed  Google Scholar 

  60. Hokanson JE, Austin MA (1996) Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3:213–219

    Article  CAS  PubMed  Google Scholar 

  61. Pizzorno JE, Murray MT (2013) Textbook of natural medicine, 4th edn. Elsevier, Amsterdam

    Google Scholar 

  62. Young JM et al (2007) Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol 100:1400–1403

    Article  CAS  PubMed  Google Scholar 

  63. Caso G, Kelly P, McNurlan MA, Lawson WE (2007) Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 99:1409–1412

    Article  CAS  PubMed  Google Scholar 

  64. Marcoff L, Thompson PD (2007) The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 49:2231–2237

    Article  CAS  PubMed  Google Scholar 

  65. Hathcock JN, Shao A (2006) Risk assessment for coenzyme Q10 (Ubiquinone). Regul Toxicol Pharmacol 45:282–288

    Article  CAS  PubMed  Google Scholar 

  66. Sander S, Coleman CI, Patel AA, Kluger J, White CM (2006) The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail 12:464–472

    Article  CAS  PubMed  Google Scholar 

  67. Kamikawa T, Kobayashi A, Yamashita T, Hayashi H, Yamazaki N (1985) Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. Am J Cardiol 56:247–251

    Article  CAS  PubMed  Google Scholar 

  68. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266–281

    Article  CAS  PubMed  Google Scholar 

  69. Wang TJ et al (2008) Vitamin D deficiency and risk of cardiovascular disease. Circulation 117:503–511

    Article  CAS  PubMed  Google Scholar 

  70. Ahmed W et al (2009) Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 153:11–16

    Article  CAS  PubMed  Google Scholar 

  71. Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288:2015–2022

    Article  Google Scholar 

  72. Bønaa KH et al (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354:1578–1588

    Article  PubMed  Google Scholar 

  73. Lonn E et al (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354:1567–1577

    Article  CAS  PubMed  Google Scholar 

  74. Stephens NG et al. (1996) Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet (London, England) 347: 781–786

    Google Scholar 

  75. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P (2000) Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:154–160

    Article  CAS  PubMed  Google Scholar 

  76. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet (London, England) 354: 447–455

    Google Scholar 

  77. Sesso HD et al (2008) Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA 300:2123–2133

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Huang H-Y, Appel LJ (2003) Supplementation of diets with alpha-tocopherol reduces serum concentrations of gamma- and delta-tocopherol in humans. J Nutr 133:3137–3140

    CAS  PubMed  Google Scholar 

  79. Dietrich M et al (2006) Does gamma-tocopherol play a role in the primary prevention of heart disease and cancer? A review. J Am Coll Nutr 25:292–299

    Article  CAS  PubMed  Google Scholar 

  80. Lagioia R et al (1992) Propionyl-L-carnitine: a new compound in the metabolic approach to the treatment of effort angina. Int J Cardiol 34:167–172

    Article  CAS  PubMed  Google Scholar 

  81. Bartels GL, Remme WJ, Pillay M, Schönfeld DH, Kruijssen DA (1994) Effects of L-propionylcarnitine on ischemia-induced myocardial dysfunction in men with angina pectoris. Am J Cardiol 74:125–310

    Article  CAS  PubMed  Google Scholar 

  82. Cacciatore L et al (1991) The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study. Drugs Exp Clin Res 17:225–235

    CAS  PubMed  Google Scholar 

  83. Davini P, Bigalli A, Lamanna F, Boem A (1992) Controlled study on L-carnitine therapeutic efficacy in post-infarction. Drugs Exp Clin Res 18:355–365

    CAS  PubMed  Google Scholar 

  84. Kamikawa T et al (1984) Effects of L-carnitine on exercise tolerance in patients with stable angina pectoris. Jpn Heart J 25:587–597

    Article  CAS  PubMed  Google Scholar 

  85. Hayashi H et al (1985) Effects of pantethine on action potential of canine papillary muscle during hypoxic perfusion. Jpn Heart J 26:289–296

    Article  CAS  PubMed  Google Scholar 

  86. Turlapaty PD, Altura BM (1980) Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease. Science 208:198–200

    Article  CAS  PubMed  Google Scholar 

  87. Altura BM (1988) Ischemic heart disease and magnesium. Magnesium 7:57–67

    CAS  PubMed  Google Scholar 

  88. McLean RM (1994) Magnesium and its therapeutic uses: a review. Am J Med 96:63–76

    Article  CAS  PubMed  Google Scholar 

  89. Purvis JR, Movahed A (1992) Magnesium disorders and cardiovascular diseases. Clin Cardiol 15:556–568

    Article  CAS  PubMed  Google Scholar 

  90. Hampton EM, Whang DD, Whang R (1994) Intravenous magnesium therapy in acute myocardial infarction. Ann Pharmacother 28:212–219

    Article  CAS  PubMed  Google Scholar 

  91. Teo KK, Yusuf S (1993) Role of magnesium in reducing mortality in acute myocardial infarction. A review of the evidence. Drugs 46:347–359

    Article  CAS  PubMed  Google Scholar 

  92. Shechter M, Kaplinsky E, Rabinowitz B (1992) The rationale of magnesium supplementation in acute myocardial infarction. A review of the literature. Arch Intern Med 152:2189–2196

    Article  CAS  PubMed  Google Scholar 

  93. Bednarz B et al (2000) Effects of oral L-arginine supplementation on exercise-induced QT dispersion and exercise tolerance in stable angina pectoris. Int J Cardiol 75:205–210

    Article  CAS  PubMed  Google Scholar 

  94. Kobayashi N, Nakamura M, Hiramori K (1999) Effects of infusion of L-arginine on exercise-induced myocardial ischemic ST-segment changes and capacity to exercise of patients with stable angina pectoris. Coron Artery Dis 10:321–326

    Article  CAS  PubMed  Google Scholar 

  95. Ceremuzyński L, Chamiec T, Herbaczyńska-Cedro K (1997) Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol 80:331–333

    Article  PubMed  Google Scholar 

  96. Tripathi P, Chandra M, Misra MK (2009) Oral administration of L-arginine in patients with angina or following myocardial infarction may be protective by increasing plasma superoxide dismutase and total thiols with reduction in serum cholesterol and xanthine oxidase. Oxid Med Cell Longev 2:231–237

    Article  PubMed  PubMed Central  Google Scholar 

  97. Schulman SP et al (2006) L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA 295:58–64

    Article  CAS  PubMed  Google Scholar 

  98. Rangel-Huerta O, Pastor-Villaescusa B, Aguilera C, Gil A (2015) A systematic review of the efficacy of bioactive compounds in cardiovascular disease: phenolic compounds. Nutrients 7:5177

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Fabio Firenzuoli (2009) Fitoterapia. Guida all’uso clinico delle piante medicinali. Elsevier, Milan

    Google Scholar 

  100. Gao Z, Xu H, Shi D, Wen C, Liu B (2012) Analysis on outcome of 5284 patients with coronary artery disease: the role of integrative medicine. J Ethnopharmacol 141:578–583

    Article  PubMed  Google Scholar 

  101. Ren S, Zhang H, Mu Y, Sun M, Liu P (2013) Pharmacological effects of Astragaloside IV: a literature review. J Tradit Chin Med 33:413–416

    Article  PubMed  Google Scholar 

  102. Zhang WD et al (2006) Astragaloside IV from Astragalus membranaceus shows cardioprotection during myocardial ischemia in vivo and in vitro. Planta Med 72:4–8

    Article  CAS  PubMed  Google Scholar 

  103. Chen P et al (2011) Astragaloside IV attenuates myocardial fibrosis by inhibiting TGF-β1 signaling in coxsackievirus B3-induced cardiomyopathy. Eur J Pharmacol 658:168–174

    Article  CAS  PubMed  Google Scholar 

  104. Qu YZ et al (2009) Astragaloside IV attenuates cerebral ischemia-reperfusion-induced increase in permeability of the blood-brain barrier in rats. Eur J Pharmacol 606:137–141

    Article  CAS  PubMed  Google Scholar 

  105. Chtourou Y et al (2015) Naringenin reduces cholesterol-induced hepatic inflammation in rats by modulating matrix metalloproteinases-2, 9 via inhibition of nuclear factor kB pathway. Eur J Pharmacol 746:96–105

    Article  CAS  PubMed  Google Scholar 

  106. Izzo AA, Di Carlo G, Borrelli F, Ernst E (2005) Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol 98:1–14

    Article  PubMed  Google Scholar 

  107. Valli G, Giardina EGV (2002) Benefits, adverse effects and drug interactions of herbal therapies with cardiovascular effects. J Am Coll Cardiol 39:1083–1095

    Article  PubMed  Google Scholar 

  108. Sofi F, Cesari F, Abbate R, Gensini GF, Casini A (2008) Adherence to Mediterranean diet and health status: meta-analysis. BMJ 337:a1344

    Article  PubMed  PubMed Central  Google Scholar 

  109. Kushi LH, Meyer KA, Jacobs DR (1999) Cereals, legumes, and chronic disease risk reduction: evidence from epidemiologic studies. Am J Clin Nutr 70:451S–458S

    CAS  PubMed  Google Scholar 

  110. Kottler BM, Ferdowsian HR, Barnard ND (2009) Effects of plant-based diets on plasma lipids. Am J Cardiol 104:947–956

    Article  CAS  Google Scholar 

  111. Sabaté J (1999) Nut consumption, vegetarian diets, ischemic heart disease risk, and all- cause mortality: evidence from epidemiologic studies. in. Am J Clin Nutr 70:500S–503S

    PubMed  Google Scholar 

  112. Nasri H, Baradaran A, Shirzad H, Rafieian-Kopaei M (2014) New concepts in nutraceuticals as alternative for pharmaceuticals. Int J Prev Med 5:1487–1499

    PubMed  PubMed Central  Google Scholar 

  113. Shukla SK, Gupta S, Ojha SK, Sharma SB (2010) Cardiovascular friendly natural products: a promising approach in the management of CVD. Nat Prod Res 24:873–898

    Article  CAS  PubMed  Google Scholar 

  114. Di Giuseppe R et al (2008) Regular consumption of dark chocolate is associated with low serum concentrations of C-reactive protein in a healthy Italian population. J Nutr 138:1939–1945

    PubMed  Google Scholar 

  115. Corti R, Flammer AJ, Hollenberg NK, Luscher TF (2009) Cocoa and cardiovascular health. Circulation 119:1433–1441

    Article  PubMed  Google Scholar 

  116. Desch S et al (2010) Low vs higher-dose dark chocolate and blood pressure in cardiovascular high-risk patients. Am J Hypertens 23:694–700

    Article  CAS  PubMed  Google Scholar 

  117. Innes AJ, Kennedy G, McLaren M, Bancroft AJ, Belch JJF (2003) Dark chocolate inhibits platelet aggregation in healthy volunteers. Platelets 14:325

    Article  CAS  PubMed  Google Scholar 

  118. Vinson JA, Proch J, Zubik L (1999) Phenol antioxidant quantity and quality in foods: Cocoa, dark chocolate, and milk chocolate. J Agric Food Chem 47:4821–4824

    Article  CAS  PubMed  Google Scholar 

  119. Grassi D et al (2012) Protective effects of flavanol-rich dark chocolate on endothelial function and wave reflection during acute hyperglycemia. Hypertension 60:827–832

    Article  CAS  PubMed  Google Scholar 

  120. Flammer AJ et al (2007) Dark chocolate improves coronary vasomotion and reduces platelet reactivity. Circulation 116:2376–2382

    Article  PubMed  Google Scholar 

  121. Grassi D, Lippi C, Necozione S, Desideri G, Ferri C (2005) Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. Am J Clin Nutr 81:611–614

    CAS  PubMed  Google Scholar 

  122. Sirtori CR, Galli C, Anderson JW, Sirtori E, Arnoldi A (2009) Functional foods for dyslipidaemia and cardiovascular risk prevention. Nutr Res Rev 22:244–261

    Article  CAS  PubMed  Google Scholar 

  123. Kuriyama S (2008) The relation between green tea consumption and cardiovascular disease as evidenced by epidemiological studies. J Nutr 138:1548S–1553S

    CAS  PubMed  Google Scholar 

  124. Sone T et al (2011) Randomized controlled trial for an effect of catechin-enriched green tea consumption on adiponectin and cardiovascular disease risk factors. Food Nutr Res 55:8326

    Article  CAS  Google Scholar 

  125. Kuriyama S et al (2006) Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA 296:1255–1265

    Article  CAS  PubMed  Google Scholar 

  126. Larsson SC (2014) Coffee, tea, and cocoa and risk of stroke. Stroke 45:309–314

    Article  PubMed  Google Scholar 

  127. Larsson SC et al (2008) Coffee and tea consumption and risk of stroke subtypes in male smokers. Stroke 39:1681–1687

    Article  CAS  PubMed  Google Scholar 

  128. Grassi D et al (2013) Tea, flavonoids, and cardiovascular health: endothelial protection. Am J Clin Nutr 98:1660S

    Article  CAS  PubMed  Google Scholar 

  129. Bonita JS, Mandarano M, Shuta D, Vinson J (2007) Coffee and cardiovascular disease: in vitro, cellular, animal, and human studies. Pharmacol Res 55:187–198

    Article  CAS  PubMed  Google Scholar 

  130. Gensini GF, Lippi D, Conti AA (2007) Past, present and future of green tea: from pleasant beverage to drug in pills? Recenti Prog Med 98:347–351

    PubMed  Google Scholar 

  131. Sofi F et al (2007) Coffee consumption and risk of coronary heart disease: a meta-analysis. Nutr Metab Cardiovasc Dis 17:209–223

    Article  CAS  PubMed  Google Scholar 

  132. Duffy SJ et al (2001) Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation 104:151

    Article  CAS  PubMed  Google Scholar 

  133. Geleijnse JM, Launer LJ, Hofman A, Pols HA, Witteman JC (1999) Tea flavonoids may protect against atherosclerosis: the Rotterdam Study. Arch Intern Med 159:2170–2174

    Article  CAS  PubMed  Google Scholar 

  134. Geleijnse JM, Launer LJ, Van Der Kuip DAM, Hofman A, Witteman JCM (2002) Inverse association of tea and flavonoid intakes with incident myocardial infarction: The Rotterdam Study. Am J Clin Nutr 75:880–886

    CAS  PubMed  Google Scholar 

  135. Alexopoulos N et al (2008) The acute effect of green tea consumption on endothelial function in healthy individuals. Eur J Cardiovasc Prev Rehabil 15:300–305

    Article  PubMed  Google Scholar 

  136. Jochmann N et al (2008) The efficacy of black tea in ameliorating endothelial function is equivalent to that of green tea. Br J Nutr 99:863–868

    Article  CAS  PubMed  Google Scholar 

  137. Kim W et al (2006) Effect of green tea consumption on endothelial function and circulating endothelial progenitor cells in chronic smokers. Circ J 70:1052–1057

    Article  CAS  PubMed  Google Scholar 

  138. Arab L, Khan F, Lam H (2013) Tea consumption and cardiovascular disease risk. Am J Clin Nutr 98:1651S–1659S

    Article  CAS  PubMed  Google Scholar 

  139. Bombardelli E, Morazzoni P (1995) Vitis vinifera L. Fitoterapia 66:291–317

    CAS  Google Scholar 

  140. De Bruyne T et al (1999) Biological evaluation of proanthocyanidin dimers and related polyphenols. J Nat Prod 62:954–958

    Article  PubMed  CAS  Google Scholar 

  141. Maffei Facinó R et al (1996) Procyanidines from Vitis vinifera seeds protect rabbit heart from ischemia/reperfusion injury: antioxidant intervention and/or iron and copper sequestering ability. Planta Med 62:495–502

    Article  PubMed  Google Scholar 

  142. Sato M, Maulik G, Ray PS, Bagchi D, Das DK (1999) Cardioprotective effects of grape seed proanthocyanidin against ischemic reperfusion injury. J Mol Cell Cardiol 31:1289–1297

    Article  CAS  PubMed  Google Scholar 

  143. Serafini M, Ghiselli A, Ferro-Luzzi A (1994) Red wine, tea, and antioxidants. Lancet 344:626

    Article  CAS  PubMed  Google Scholar 

  144. Bagchi D et al (2000) Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention. Toxicology 148:187–197

    Article  CAS  PubMed  Google Scholar 

  145. Opie LH, Lecour S (2007) The red wine hypothesis: from concepts to protective signalling molecules. Eur Heart J 28:1683–1693

    Article  CAS  PubMed  Google Scholar 

  146. Bhat KPL, Kosmeder JW, Pezzuto JM (2001) Biological effects of resveratrol. Antioxid Redox Signal 3:1041–1064

    Article  CAS  Google Scholar 

  147. Blanco-Colio LM et al (2000) Red wine intake prevents nuclear factor-kappaB activation in peripheral blood mononuclear cells of healthy volunteers during postprandial lipemia. Circulation 102:120–126

    Article  Google Scholar 

  148. Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5:493–506

    Article  CAS  PubMed  Google Scholar 

  149. Das M, Das DK (2010) Resveratrol and cardiovascular health. Mol Aspects Med 31:503–512

    Article  CAS  PubMed  Google Scholar 

  150. Cheng B, Hung CT, Chiu W (2002) Herbal medicine and anaesthesia in Hong Kong. Med J 8:123–130

    CAS  Google Scholar 

  151. Fasinu PS, Bouic PJ, Rosenkranz B (2012) An overview of the evidence and mechanisms of herb-drug interactions. Front Pharmacol 3:69

    Article  PubMed  PubMed Central  Google Scholar 

  152. Zhang J et al (2008) Compound Salvia droplet pill, a traditional Chinese medicine, for the treatment of unstable angina pectoris: a systematic review. Med Sci Monit 14:RA1–7

    PubMed  Google Scholar 

  153. Wu T, Ni J, Wu J (2008) Danshen (Chinese medicinal herb) preparations for acute myocardial infarction. Cochrane database Syst Rev CD004465

    Google Scholar 

  154. Zatalia SR, Sanusi H (2013) The role of antioxidants in the pathophysiology, complications, and management of diabetes mellitus. Acta Med Indones 45:141–7

    PubMed  Google Scholar 

  155. Smith PF, Maclennan K, Darlington CL (1996) The neuroprotective properties of the Ginkgo biloba leaf: a review of the possible relationship to platelet-activating factor (PAF). J Ethnopharmacol 50:131–139

    Article  CAS  PubMed  Google Scholar 

  156. Silvio S, Loggia RD, Tubaro A, Bombardelli E (1993) Anti-inflammatory activity of Ginkgo biloba flavonoids. Planta Med 59:588

    Google Scholar 

  157. Singh B, Kaur P, Gopichand Singh RD, Ahuja PS (2008) Biology and chemistry of Ginkgo biloba. Fitoterapia 79:401–418

    Article  CAS  PubMed  Google Scholar 

  158. Dong XX et al (2007) Ginkgo biloba extract reduces endothelial progenitor-cell senescence through augmentation of telomerase activity. J Cardiovasc Pharmacol 49:111–115

    Article  CAS  PubMed  Google Scholar 

  159. Diamond BJ et al (2000) Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil 81:668–678

    CAS  PubMed  Google Scholar 

  160. Calapai G et al (2000) Neuroprotective effects of Ginkgo biloba extract in brain ischemia are mediated by inhibition of nitric oxide synthesis. Life Sci 67:2673–2683

    Article  CAS  PubMed  Google Scholar 

  161. Vellas B et al (2012) Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 11:851–859

    Article  CAS  PubMed  Google Scholar 

  162. Kuller LH et al (2010) Does ginkgo biloba reduce the risk of cardiovascular events? Circ Cardiovasc Qual Outcomes 3:41–47

    Article  PubMed  Google Scholar 

  163. Weinmann S, Roll S, Schwarzbach C, Vauth C, Willich SN (2010) Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr 10:14

    Article  PubMed  PubMed Central  Google Scholar 

  164. Mahady GB (2002) Ginkgo biloba for the prevention and treatment of cardiovascular disease: a review of the literature. J Cardiovasc Nurs 16:21–32

    Article  PubMed  Google Scholar 

  165. Wang J, Zhou S, Bronks R, Graham J, Myers S (2007) Supervised exercise training combined with ginkgo biloba treatment for patients with peripheral arterial disease. Clin Rehabil 21:579–586

    Article  PubMed  Google Scholar 

  166. Pittler MH, Ernst E (2005) Complementary therapies for peripheral arterial disease: systematic review. Atherosclerosis 181:1–7

    Article  CAS  PubMed  Google Scholar 

  167. Schweizer J, Hautmann C (1999) Comparison of two dosages of ginkgo biloba extract EGb 761 in patients with peripheral arterial occlusive disease Fontaine’s stage IIb. A randomised, double-blind, multicentric clinical trial. Arzneimittelforschung 49:900–904

    CAS  PubMed  Google Scholar 

  168. Lim S et al (2011) Egb761, a ginkgo biloba extract, is effective against atherosclerosis in vitro, and in a rat model of type 2 diabetes. PLoS One 6:E20301

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  169. Köse K, Doğan P, Aşçioğlu M, Aşçioğlu O (1997) In vitro antioxidant effect of Ginkgo biloba extract (EGb 761) on lipoperoxidation induced by hydrogen peroxide in erythrocytes of Behçet’s patients. Jpn J Pharmacol 75:253–258

    Article  PubMed  Google Scholar 

  170. Le Bars PL et al (1997) A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 278:1327–1332

    Article  PubMed  Google Scholar 

  171. Hopfenmüller W (1994) Evidence for a therapeutic effect of Ginkgo biloba special extract. Meta-analysis of 11 clinical studies in patients with cerebrovascular insufficiency in old age. Arzneimittelforschung 44:1005–1013

    PubMed  Google Scholar 

  172. Guo L, Mei N, Liao W, Chan P-C, Fu PP (2010) Ginkgo biloba extract induces gene expression changes in xenobiotics metabolism and the Myc-centered network. OMICS 14:75–90

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  173. Gardner CD, Zehnder JL, Rigby AJ, Nicholus JR, Farquhar JW (2007) Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trial. Blood Coagul Fibrinolysis 18:787–793

    Article  PubMed  Google Scholar 

  174. McKay DL, Blumberg JB (2007) Cranberries (Vaccinium macrocarpon) and cardiovascular disease risk factors. Nutr Rev 65:490–502

    Article  PubMed  Google Scholar 

  175. Blumberg JB et al (2013) Cranberries and their bioactive constituents in human health. Adv Nutr 4:618–632

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  176. Morazzoni P, Livio S, Scilingo A, Malandrino S (1991) Vaccinium myrtillus anthocyanosides pharmacokinetics in rats. Arzneimittelforschung 41:128–131

    CAS  PubMed  Google Scholar 

  177. Rimando AM, Kalt W, Magee JB, Dewey J, Ballington JR (2004) Resveratrol, pterostilbene, and piceatannol in Vaccinium berries. J Agric Food Chem 52:4713–4719

    Article  CAS  PubMed  Google Scholar 

  178. Chu W, Cheung SCM, Lau R et al. (2008) Bilberry (Vaccinium myrtillus L.). In: Benzie IFF and Wachtel-Galor S (eds) Herbal medicine: biomolecular and clinical aspects, 2nd edn. CRC Press/Taylor and Francis, Boca Raton, FL

    Google Scholar 

  179. Persson IA-L, Persson K, Andersson RGG (2009) Effect of Vaccinium myrtillus and its polyphenols on angiotensin-converting enzyme activity in human endothelial cells. J Agric Food Chem 57:4626–4629

    Article  CAS  PubMed  Google Scholar 

  180. Wilson T, Porcari JP, Harbin D (1998) Cranberry extract inhibits low density lipoprotein oxidation. Life Sci 62:PL381–386

    Article  CAS  PubMed  Google Scholar 

  181. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D (1993) Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 342:1007–1011

    Article  CAS  PubMed  Google Scholar 

  182. Hertog MG et al (1995) Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med 155:381–386

    Article  CAS  PubMed  Google Scholar 

  183. Keli SO, Hertog MG, Feskens EJ, Kromhout D (1996) Dietary flavonoids, antioxidant vitamins, and incidence of stroke: the Zutphen study. Arch Intern Med 156:637–642

    Article  CAS  PubMed  Google Scholar 

  184. Costantino L, Albasini A, Rastelli G, Benvenuti S (1992) Activity of polyphenolic crude extracts as scavengers of superoxide radicals and inhibitors of xanthine oxidase. Planta Med 58:342–344

    Article  CAS  PubMed  Google Scholar 

  185. Bertuglia S, Malandrino S, Colantuoni A (1995) Effect of vaccinium myrtillus anthocyanosides on ischaemia reperfusion injury in hamster cheek pouch microcirculation. Pharmacol Res 31:183–187

    Article  CAS  PubMed  Google Scholar 

  186. Matsunaga N, Chikaraishi Y, Shimazawa M, Yokota S, Hara H (2010) Vaccinium myrtillus (bilberry) extracts reduce angiogenesis in vitro and in vivo. Evid Based Complement Altern Med 7:47–56

    Article  Google Scholar 

  187. Rivlin RS (2001) Historical perspective on the use of garlic. J Nutr 131:951S–954

    CAS  PubMed  Google Scholar 

  188. Rana SV, Pal R, Vaiphei K, Sharma SK, Ola RP (2011) Garlic in health and disease. Nutr Res Rev 24:60–71

    Article  CAS  PubMed  Google Scholar 

  189. Shouk R, Abdou A, Shetty K, Sarkar D, Eid AH (2014) Mechanisms underlying the antihypertensive effects of garlic bioactives. Nutr Res 34:106–115

    Article  CAS  PubMed  Google Scholar 

  190. Capraz M, Dilek M, Akpolat T (2007) Garlic, hypertension and patient education. Int J Cardiol 121:130–131

    Article  PubMed  Google Scholar 

  191. Tattelman E (2005) Health effects of garlic. Am Fam Physician 72:103–106

    PubMed  Google Scholar 

  192. Orekhov AN, ünwald J (1997) Effects of garlic on atherosclerosis. Nutrition 13:656–663

    Article  CAS  PubMed  Google Scholar 

  193. Gardiner P, Graham RE, Legedza ATR, Eisenberg DM, Phillips RS (2006) Factors associated with dietary supplement use among prescription medication users. Arch Intern Med 166:1968–1974

    Article  PubMed  Google Scholar 

  194. Gorinstein S et al (2007) The atherosclerotic heart disease and protecting properties of garlic: contemporary data. Mol Nutr Food Res 51:1365–1381

    Article  CAS  PubMed  Google Scholar 

  195. Tsai CW, Chen HW, Sheen LY, Lii CK (2012) Garlic: health benefits and actions. Biomed 2:17–29

    Article  Google Scholar 

  196. Agarwal KC (1996) Therapeutic actions of garlic constituents. Med Res Rev 16:111–124

    Article  CAS  PubMed  Google Scholar 

  197. Jung F, Jung E, Pindur G, Kiesewetter H (2007) Effect of different garlic preparations on the fluidity of blood, fibrinolytic activity, and peripheral microcirculation in comparison with placebo. Planta Med 56:668–668

    Article  Google Scholar 

  198. Banerjee SK, Maulik SK (2002) Effect of garlic on cardiovascular disorders: a review. Nutr J 1:4

    Article  PubMed  PubMed Central  Google Scholar 

  199. Beretz A, Cazenave JP (1991) Old and new natural products as the source of modern antithrombotic drugs. Planta Med 57:S68–S72

    Article  Google Scholar 

  200. Legnani C et al (1993) Effects of a dried garlic preparation on fibrinolysis and platelet aggregation in healthy subjects. Arzneimittelforschung 43:119–122

    CAS  PubMed  Google Scholar 

  201. Bordia A, Verma SK, Srivastava KC (1998) Effect of garlic (Allium sativum) on blood lipids, blood sugar, fibrinogen and fibrinolytic activity in patients with coronary artery disease. Prostaglandins, Leukot Essent Fat Acids 58:257–263

    Article  CAS  Google Scholar 

  202. Rahman K (2007) Effects of garlic on platelet biochemistry and physiology. Mol Nutr Food Res 51:1335–1344

    Article  CAS  PubMed  Google Scholar 

  203. Srivastava KC (1986) Evidence for the mechanism by which garlic inhibits platelet aggregation. Prostaglandins Leukot Med 22:313–321

    Article  CAS  PubMed  Google Scholar 

  204. Bordia A (1978) Effect of garlic on human platelet aggregation in vitro. Atherosclerosis 30:355–360

    Article  CAS  PubMed  Google Scholar 

  205. Bordia A, Verma SK, Srivastava KC (1996) Effect of garlic on platelet aggregation in humans: a study in healthy subjects and patients with coronary artery disease. Prostaglandins Leukot Essent Fat Acids 55:201–205

    Article  CAS  Google Scholar 

  206. Pittler MH, Ernst E (2007) Clinical effectiveness of garlic (Allium sativum). Mol Nutr Food Res 51:1382–1385

    Article  CAS  PubMed  Google Scholar 

  207. Pedraza-Chaverrí J, Medina-Campos ON, Ávila-Lombardo R, Berenice Zúñiga-Bustos A, Orozco-Ibarra M (2006) Reactive oxygen species scavenging capacity of different cooked garlic preparations. Life Sci 78:761–770

    Article  PubMed  CAS  Google Scholar 

  208. Mahdavi-Roshan M et al (2015) Effect of garlic powder tablet on carotid intima-media thickness in patients with coronary artery disease: a preliminary randomized controlled trial. Nutr Health 22:143–155

    Article  CAS  Google Scholar 

  209. Breithaupt-Grügler K, Ling M, Boudoulas H, Belz GG (1997) Protective effect of chronic garlic intake on elastic properties of aorta in the elderly. Circulation 96:2649–2655

    Article  Google Scholar 

  210. Ried K, Frank OR, Stocks NP, Fakler P, Sullivan T (2008) Effect of garlic on blood pressure: a systematic review and meta-analysis. BMC Cardiovasc Disord 8:13

    Article  PubMed  PubMed Central  Google Scholar 

  211. Stevinson C, Pittler MH, Ernst E (2000) Garlic for treating hypercholesterolemia. A meta-analysis of randomized clinical trials. Ann Intern Med 133:420–429

    Article  CAS  PubMed  Google Scholar 

  212. Warshafsky S, Kamer RS, Sivak SL (1993) Effect of garlic on total serum cholesterol. A meta-analysis. Ann Intern Med 119:599–605

    Article  CAS  PubMed  Google Scholar 

  213. Rahman K (2010) in Bioact Foods Promot Heal 235–244. doi:10.1016/B978-0-12-374628-3.00016-5

  214. Budoff M (2006) Aged garlic extract retards progression of coronary artery calcification. J Nutr 136:741S–744S

    CAS  PubMed  Google Scholar 

  215. Ried K, Toben C, Fakler P (2013) Effect of garlic on serum lipids: an updated meta-analysis. Nutr Rev 71:282–299

    Article  PubMed  Google Scholar 

  216. Silagy CA, Neil HA (1994) A meta-analysis of the effect of garlic on blood pressure. J Hypertens 12:463–468

    Article  CAS  PubMed  Google Scholar 

  217. Scharbert G, Kalb ML, Duris M, Marschalek C, Kozek-Langenecker SA (2007) Garlic at dietary doses does not impair platelet function. Anesth Analg 105:1214–1218

    Article  PubMed  Google Scholar 

  218. Owens C, Baergen R, Puckett D (2014) Online sources of herbal product information. Am J Med 127:109–115

    Article  PubMed  Google Scholar 

  219. Ammon HP, Händel M (1981) Crataegus, toxicology and pharmacology. I. Toxicity. Planta Med 43:105–120

    Article  CAS  PubMed  Google Scholar 

  220. Ammon HP, Händel M (1981) Crataegus, toxicology and pharmacology. II. Pharmacodynamics. Planta Med 43:209–239

    Article  CAS  PubMed  Google Scholar 

  221. Ammon HP, Händel M (1981) Crataegus, toxicology and pharmacology. III. Pharmacodynamics and pharmacokinetics. Planta Med 43:313–322

    Article  CAS  PubMed  Google Scholar 

  222. Blesken R (1992) Crataegus in cardiology. Fortschr Med 110:290–292

    CAS  PubMed  Google Scholar 

  223. Nasa Y, Hashizume H, Hoque AN, Abiko Y (1993) Protective effect of crataegus extract on the cardiac mechanical dysfunction in isolated perfused working rat heart. Arzneimittelforschung 43:945–949

    CAS  PubMed  Google Scholar 

  224. Osher HL, Katz KH, Wagner DJ (1951) Khellin in the treatment of angina pectoris. N Engl J Med 244:315–321

    Article  CAS  PubMed  Google Scholar 

  225. Anrep GV, Kenawy MR, Barsoum GS (1949) The coronary vasodilator action of khellin. Am Heart J 37:531–542

    Article  CAS  PubMed  Google Scholar 

  226. Conn JJ, Kissane RW, Koon RA, Clark TE (1953) The treatment of angina pectoris with khellin. Ann Intern Med 38:23–27

    Article  CAS  PubMed  Google Scholar 

  227. Li J, Chen CX, Shen YH (2011) Effects of total glucosides from paeony (Paeonia lactiflora Pall) roots on experimental atherosclerosis in rats. J Ethnopharmacol 135:469–475

    Article  CAS  PubMed  Google Scholar 

  228. Long J et al (2012) Cardioprotective effect of total paeony glycosides against isoprenaline-induced myocardial ischemia in rats. Phytomedicine 19:672–676

    Article  CAS  PubMed  Google Scholar 

  229. Luo C et al (2013) Protection of H9c2 rat cardiomyoblasts against oxidative insults by total paeony glucosides from Radix Paeoniae Rubrae. Phytomedicine 21:20–24

    Article  CAS  PubMed  Google Scholar 

  230. Wei S (2015) Progress on cardiovascular protections and mechanism research of puerarin. Zhongguo Zhong Yao Za Zhi 40:2278–2284

    CAS  PubMed  Google Scholar 

  231. Lu Q et al (2014) Puerarin attenuates calcification of vascular smooth muscle cells. Am J Chin Med 42:337–347

    Article  CAS  PubMed  Google Scholar 

  232. Yu W et al (2014) Flos Puerariae extract prevents myocardial apoptosis via attenuation oxidative stress in streptozotocin-induced diabetic mice. PLoS One 9, e98044

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  233. Bao L et al (2015) The anti-atherosclerotic effects of puerarin on induced-atherosclerosis in rabbits. Biomed Pap Med Fac Univ Palacký, Olomouc, Czechoslov 159:53–59

    Google Scholar 

  234. Zhou Y-X, Zhang H, Peng C (2014) Puerarin: a review of pharmacological effects. Phytother Res 28:961–975

    Article  CAS  PubMed  Google Scholar 

  235. Fioranelli M et al. (2016) Efficacia di Arnica Comp.- Heel® nel ridurre il rischio di eventi cardiovascolari in pazienti con coronaropatia stabile. Minerva Cardioangiol 64:1–8

    Google Scholar 

  236. Dash B (2006) Herbal treatment for heart disease. Health Armony B. Jain Publisher Ltd, New Delhi

    Google Scholar 

  237. Chen C et al (2015) Natural products for antithrombosis. Evidence-Based Complement Altern Med 2015, 876426

    Google Scholar 

  238. Rozanski A, Blumenthal JA, Kaplan J (1999) Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 99:2192–2217

    Article  CAS  PubMed  Google Scholar 

  239. Balestri M, Calati R, Serretti A, De Ronchi D (2014) Genetic modulation of personality traits: a systematic review of the literature. Int Clin Psychopharmacol 29:1–15

    Article  PubMed  Google Scholar 

  240. Rademaker AR, Kleber RJ, Geuze E, Vermetten E (2009) Personality dimensions harm avoidance and self-directedness predict the cortisol awakening response in military men. Biol Psychol 81:177–183

    Article  PubMed  Google Scholar 

  241. Dimopoulou C et al (2013) Increased prevalence of anxiety-associated personality traits in patients with Cushing’s disease: a cross-sectional study. Neuroendocrinology 97:139–145

    Article  CAS  PubMed  Google Scholar 

  242. Yoda N et al (2008) Classification of adult patients with type 2 diabetes using the Temperament and Character Inventory. Psychiatry Clin Neurosci 62:279–285

    Article  PubMed  Google Scholar 

  243. Joyce PR, Mulder RT, Cloninger CR (1994) Temperament and hypercortisolemia in depression. Am J Psychiatry 151:195–198

    Article  CAS  PubMed  Google Scholar 

  244. Wang S et al (1997) Relationships between hormonal profile and novelty seeking in combat-related posttraumatic stress disorder. Biol Psychiatry 41:145–151

    Article  CAS  PubMed  Google Scholar 

  245. Simic I et al (2013) A preliminary evaluation of leukocyte phospho-glucocorticoid receptor as a potential biomarker of depressogenic vulnerability in healthy adults. Psychiatry Res 209:658–664

    Article  CAS  PubMed  Google Scholar 

  246. Capitanio JP et al (2008) Personality and serotonin transporter genotype interact with social context to affect immunity and viral set-point in simian immunodeficiency virus disease. Brain Behav Immun 22:676–689

    Article  CAS  PubMed  Google Scholar 

  247. Carnevali L, Sgoifo A (2014) Vagal modulation of resting heart rate in rats: the role of stress, psychosocial factors, and physical exercise. Front Physiol 5:118

    Article  PubMed  PubMed Central  Google Scholar 

  248. Ader R (2011) Psychoneuroimmunology, Two-Volume Set. Elsevier

    Google Scholar 

  249. Mittleman MA et al (1995) Triggering of acute myocardial infarction onset by episodes of anger. Determinants of Myocardial Infarction Onset Study Investigators. Circulation 92:1720–5

    Article  CAS  PubMed  Google Scholar 

  250. Stegano L (2009) Psicofisiologia. Dalla genetica comportamentale alle attività cognitive. Zanichelli

    Google Scholar 

  251. Janszky I, Ahnve S, Lundberg I, Hemmingsson T (2010) Early-onset depression, anxiety, and risk of subsequent coronary heart disease: 37-year follow-up of 49,321 young Swedish men. J Am Coll Cardiol 56:31–37

    Article  PubMed  Google Scholar 

  252. Dimsdale JE (2008) Psychological stress and cardiovascular disease. J Am Coll Cardiol 51:1237–1246

    Article  PubMed  PubMed Central  Google Scholar 

  253. Wittstein IS et al (2005) Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 352:539–548

    Article  CAS  PubMed  Google Scholar 

  254. Steptoe A, Brydon L (2005) Associations between acute lipid stress responses and fasting lipid levels 3 years later. Health Psychol 24:601–607

    Article  PubMed  Google Scholar 

  255. Schneider RH et al (2012) Stress reduction in the secondary prevention of cardiovascular disease: randomized, controlled trial of transcendental meditation and health education in blacks. Circ Cardiovasc Qual Outcomes 5:750–758

    Article  PubMed  Google Scholar 

  256. Giltay EJ, Kamphuis MH, Kalmijn S, Zitman FG, Kromhout D (2006) Dispositional optimism and the risk of cardiovascular death: the Zutphen Elderly Study. Arch Intern Med 166:431–436

    PubMed  Google Scholar 

  257. Ornish D et al (1990) Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 336:129

    Article  CAS  PubMed  Google Scholar 

  258. Ornish D et al (1998) Intensive lifestyle changes for reversal of coronary heart disease. JAMA 280:2001–2007

    Article  CAS  PubMed  Google Scholar 

  259. Gould KL et al (1995) Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. JAMA 274:894–901

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiological, Thoracic and Vascular Sciences, Padua University Medical School, Padova, Italy

    Carlo Dal Lin M.D., Marco Silvestro N.D., Raffaele Migliorini M.D. & Francesco Tona M.D., Ph.D.

  2. Department of Nuclear Physics, Sub-Nuclear and Radiation, Guglielmo Marconi University, Rome, Italy

    Massimo Fioranelli M.D.

Authors
  1. Carlo Dal Lin M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marco Silvestro N.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raffaele Migliorini M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Francesco Tona M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Massimo Fioranelli M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlo Dal Lin M.D. .

Editor information

Editors and Affiliations

  1. Department of Nuclear Physics, Guglielmo Marconi University, Rome, Italy

    Massimo Fioranelli

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Dal Lin, C., Silvestro, M., Migliorini, R., Tona, F., Fioranelli, M. (2017). Integrated Approach to Coronary Artery Disease. In: Fioranelli, M. (eds) Integrative Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-319-40010-5_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-40010-5_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-40008-2

  • Online ISBN: 978-3-319-40010-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation